Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694693 | 1.00 | ALDH1A1 (0.60) | ALDH1A1EPHX1TP53GRIK1DPP4 | |
| SCHEMBL7250582 | 1.00 | ALDH1A1 (0.60) | ALDH1A1EPHX1TP53GRIK1DPP4 | |
| SCHEMBL1255799 | 1.00 | ALDH1A1 (0.60) | ALDH1A1EPHX1TP53GRIK1DPP4 | |
| SCHEMBL7250575 | 1.00 | ALDH1A1 (0.60) | ALDH1A1EPHX1TP53GRIK1DPP4 | |
| SCHEMBL5362998 | 1.00 | ALDH1A1 (0.60) | ALDH1A1EPHX1TP53GRIK1DPP4 | |
| SCHEMBL7250579 | 1.00 | ALDH1A1 (0.60) | ALDH1A1EPHX1TP53GRIK1DPP4 | |
| SCHEMBL5416686 | 1.00 | ALDH1A1 (0.60) | ALDH1A1EPHX1TP53GRIK1DPP4 | |
| Hydrochloric Acid SCHEMBL6778606 | 0.98 | ALDH1A1 (0.58) | ALDH1A1EPHX1TP53GRIK1DPP4 | |
| SCHEMBL5528291 | 0.98 | ALDH1A1 (0.58) | ALDH1A1EPHX1TP53GRIK1DPP4 | |
| Hydrochloric Acid SCHEMBL5368319 | 0.98 | ALDH1A1 (0.58) | ALDH1A1EPHX1TP53GRIK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229144-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2003-12-11 | — | — | US | claimed |
| US-20020025949-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2002-02-28 | — | — | US | claimed |
| JP-2001515483-A | — | — | 2001-09-18 | — | — | JP | claimed |
| EP-0969823-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-01-12 | — | — | EP | claimed |
| WO-1998040055-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-09-17 | — | — | WO | claimed |
| CN-109790114-B | Novel chiral ligand, metal chelate, various unnatural amino acids and synthesis method of maraviroc and key intermediate thereof | 中国科学院上海药物研究所 | 2025-03-07 | — | — | CN | disclosed |
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-12-29 | — | — | US | disclosed |
| EP-3521274-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-08-07 | — | — | EP | disclosed |
| US-20190233456-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-08-01 | — | — | US | disclosed |
| CN-109790114-A | Novel chiral ligands, metallo-chelate, a variety of unnatural amino acids, the synthetic method of Malawi's promise and its key intermediate | 中国科学院上海药物研究所 | 2019-05-21 | — | — | CN | disclosed |
| CN-101641086-B | Polypeptide membranes and methods | ARTIFICIAL CELL TECHNOLOGIES INC | 2015-04-22 | — | — | CN | disclosed |
| CN-103357007-A | Immunogenic compositions and methods of use | ARTIFICIAL CELLTECH | 2013-10-23 | — | — | CN | disclosed |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | QUEEN'S UNIVERSITY AT KINGSTON AND NEUROCHEM, INC. | 2003-10-16 | — | — | US | disclosed |
| US-6632921-B1 | Administering as topical fungicide against Candida | G. D SEARLE & CO | 2003-10-14 | — | — | US | disclosed |
| WO-2002073208-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-09-19 | — | — | WO | disclosed |
| US-20020025949-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2002-02-28 | — | — | US | disclosed |
| US-6306909-B1 | AMINOACID DERIVATIVES AND ESTERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-23 | — | — | US | disclosed |
| EP-0969823-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-01-12 | — | — | EP | disclosed |
| US-5942600-A | COMPOUNDS WITH SELECTIVE CONTROL OF FUNGAL ORGANISM CANDIDA ALBICANS FOR TREATMENT IN HUMANS, FOR EXAMPLE THOSE WITH WEAKENED IMMUNE SYSTEMS DUE TO AIDS; SPECIES-SPECIFIC CONTROL | G. D. SEARLE & CO. (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1998040055-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229144-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | ALDH1A1 712/4885EPHX1 141/4885TP53 4644/4885 |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | SLC1A2, SLC1A1, SLC1A3 | ALDH1A1 432/4885EPHX1 358/4885TP53 4751/4885 |
| US-10875883-B2 | Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof | PRMT3, GRIN3A, RAMP3 | ALDH1A1 3474/4885EPHX1 3484/4885TP53 4612/4885 |
| US-20190233456-A1 | METHOD FOR SYNTHESIZING NOVEL CHIRAL LIGAND, METAL CHELATE, A VARIETY OF NON-NATURAL AMINO ACIDS, MARAVIROC AND KEY INTERMEDIATE THEREOF | PRMT3, GRIN3A, RAMP3 | ALDH1A1 3474/4885EPHX1 3484/4885TP53 4612/4885 |
| US-20020025949-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | ALDH1A1 712/4885EPHX1 141/4885TP53 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.